Balloon catheter hypoxic abdominal and pelvic perfusion with tumour necrosis factor-alpha, Melphalan and Mitomycin C: A pharmacokinetic study in pigs

European Journal of Surgical Oncology

Volumn 30, Issue 6, 2004, Pages 699-707

  van IJken, M G A ^a   de Bruijn, E A ^b   ten Hagen, T L M ^a   de Boeck, G ^b   van Eijck, C H J ^a   Eggermont, A M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Abdomen; Ballooncatheter; Hypoxic perfusion; Melphalan; Mitomycin C; Pelvis; Pigs; Tumour necrosis factor alpha

Indexed keywords

MELPHALAN; MITOMYCIN C; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BALLOON CATHETER; BLOOD SAMPLING; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG LIVER LEVEL; EXPERIMENTAL SURGERY; HYPOXIA; LIVER BLOOD VESSEL; METHODOLOGY; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SWINE; SYSTEMIC CIRCULATION; VALIDATION PROCESS;

ABDOMINAL NEOPLASMS; ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; BALLOON OCCLUSION; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; MELPHALAN; MITOMYCIN; MODELS, ANIMAL; PELVIC NEOPLASMS; SWINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4043086430     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2004.03.015     Document Type: Article

References (42)

1. Lillemoe K.D. Current management of pancreatic carcinoma Ann Surg 221 1995 133-148
2. Hunstad D.A. Norton J.A. Management of pancreatic carcinoma Surg Oncol 4 1995 61-74
3. Ahlgren J.D. Chemotherapy for pancreatic carcinoma Cancer 78 1996 654-663
4. Fraker D.L. Alexander H.R. Thom A.K. Use of tumor necrosis factor in isolated hepatic perfusion Circ Shock 44 1994 45-50
5. Hill S. Fawcett W.J. Sheldon J. et al. Low-dose tumor necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion Br J Surg 80 1993 995-997
6. Blick M. Sherwin S.A. Rosenblum M. Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients Cancer Res 471 1987 2986-2989
7. Selby P. Hobbs S. Viner C. et al. Tumor necrosis factor in man: clinical and biological observations Br J Cancer 56 1987 803-808
8. Eggermont A.M.M. Schraffordt Koops H. Liénard D. et al. Isolated limb perfusion with high-dose tumor necrosis factor-a in combination with interferon-g and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial J Clin Oncol 14 1996 2653-2665
9. Eggermont A.M.M. Schraffordt Koops A.M.M. Klausner J.M. et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter european experience Ann Surg 224 1996 756-765
10. Eggermont A.M.M. Schraffordt Koops H. Klausner J.M. et al. Limb salvage by isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced extremity soft tissue sarcomas: results of 270 perfusions in 246 patients Proc Am Soc Clin Oncol 11 1999 497
11. Van der Veen A.H. Seynhaeve A.L.B. Breurs J. et al. In vivo isolated kidney perfusion with tumor necrosis factor in tumor bearing rats B J Cancer 79 1999 433-439
12. Alexander H.R. Baartlett D.L. Libutti S.K. et al. Isolated hepatic perfusion With tumor necrosis factor-alpha and melphalan for unresectable cancers confined to the liver J Clin Oncol 16 1998 1479-1489
13. Van IJken M.G.A. de Bruijn E.A. de Boeck G. et al. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melpphalan and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs Ann Surg 228 1998 763-770
14. Krementz E.T. Ryan R.F. Muchmore J.H. et al. Hyperthermic regional perfusion for melanoma of the limbs. Cutaneous melanoma, 2nd ed. Philadelphia: Lippincott; 1985. p. 403-26.
15. Van de Velde C.J.H. Kothuis B.J.L. Barenbrug H.W.M. et al. A successful technique of in-vivo isolated liver perfusion in pigs J Surg Res 41 1986 593
16. Turk P.S. Belliveau J.F. Darnowski J.W. et al. Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique Arch Surg 128 1993 533-539
17. Averbach A.M. Stuart O.A. Sugarbaker T.A. Intra-aortic stop-flow infusion: pharmacokinetic feasibility study of regional chemotherapy for unresectable gastrointestinal cancers Ann Surg Oncol 2 1995 325-331
18. Averbach A.M. Stuart O.A. Sugarbaker T.A. Pharmacokinetic studies of intra-aortic-stop-flow infusion with 14-C labeled mitomycin C J Surg Res 59 1995 415-419
19. Averbach A.M. Sugarbaker T.A. Advanced gastric cancer: review of regional chemotherapy trials and treatment strategies using stop-flow infusion Reg Cancer Treat 8 67 1995 67F-76F
20. Lorenz M. Petrowsky H. Heinrich S. et al. Isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer Eur J Surg Oncol 24 1998 542-547
21. Wanebo H.J. Chung M.A. Levy A.I. et al. Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon-occlusion technique Ann Surg Oncol 3 1996 295-303
22. Wanebo H.J. Belliveau J.F. A pharmacokinetic model and the clinical pharmacology of cis-platinum, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion Cancer Chemother Pharmacol 43 1999 427-434
23. Aigner K.R. Aortic stopflow infusion (ASI) and hypoxic abdominal perfusion (HAP) for disseminated bulky peritoneal carcinomatosis-rationale and technique Reg Cancer Treat 6 1993 3
24. Aigner K.R. Pelvic stopflow infusion and hypoxic pelvic perfusion-techniques and pharmacokinetics Reg Cancer 1998 Treat
25. Aigner K.R. Kaevel K. Pelvic stopflow infusion (PSI) and hypoxic pelvic perfusion (HPP) with mitomycin and melphalan for recurrent rectal cancer Reg Cancer Treat 7 1994 6-11
26. Guadigni V.S. Lorenz M. Letters to the editor Eur J Surg Onc 25 1999 339-340
27. Lorenz M. Heinrich S. Staib-Sebler E. et al. Regional chemotherapy in the treatment of advanced pancreatic cancer-is it relevant? Eur J Cancer 36 2000 957-965
28. Eggermont A.M.M. Van Ijken M.G.A. Van Etten et al. Isolated hypoxic hepatic perfusion (IHHP) using ballooncatheter techniques: from laboratory to the clinic towards a percutaneous procedure HepatoGastroenterology 47 2000 776-781
29. Engelberts I. Moller A. Schoen G.J.M. et al. Evaluation of measurement of human TNF in plasma by ELISA Lymphokine Cytokine Res 10 1991 69-76
30. De Boeck G. Van Cauwenberghe K. Eggermont A.M.M. et al. Determination of melphalan and hydrolysis products in body fluids by GC-MS J High Res Chromatogr 20 1997 697-700
31. Tjaden U.R. de Bruijn E.A. Chromatographic analysis of anticancer drugs J Chromatogr 531 1990 235-294
32. Fajardo L.F. Kwan H.H. Kowalski J. et al. Dual role of tumor necrosis factor-alpha in angiogenesis Am J Pathol 140 1992 539-544
33. De Wilt J.H. Manusama E.R. Van Tiel S.T. et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats B J Cancer 80 1999 161-166
34. Colins J.M. et al. Pharmacologic rationale for regional drug delivery J Clin Oncol 2 1984 498-504
35. Thompson J.F. Liu M. Watson L.D. et al. percutaneous aortic 'stop-flow' infusion technique for regional cytotoxic therapy of the abdomen and pelvis Reg Cancer Treat 7 1994 202-207
36. Sugarbaker P.H. In DeVita VT, Hellman S, Rosenberg SA (eds). Principles of cancer treatment. New York: Lippincott-Raven; 1992. p. 75.
37. Vaupel P. Kallinowski F. Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review Cancer Res 49 1989 6449-6465
38. Teicher B.A. Lazo J.S. Sartorelli A.C. Classification of antineoplastic agents by their selective toxicities towards oxygenated and hypoxic tumor cells Cancer Res 41 1981 73-81
39. Liénard D. Ewalenko P. Delmotte J.J. et al. High doses of tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma J Clin Oncol 10 1992 52-60
40. Fraker D.L. Alexander H.R. Andrich M. et al. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study J Clin Oncol 14 1996 479-489
41. Renard N. Liénard D. Lespagnard L. et al. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rhTNFalpha) Int J Cancer 57 1994 656-663
42. Nooijen P.T.G.A. Manusama E.R. Eggermont A.M.M. et al. Synergistic antitumour effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathologic, immunohistochemical and electron microscopic study Br J Cancer 74 1996 1908-1915